Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction
Acute Myocardial Infarction
About this trial
This is an interventional treatment trial for Acute Myocardial Infarction focused on measuring Acute myocardial infarction, primary angioplasty, streptokinase, microvasculature
Eligibility Criteria
Inclusion criteria: Continuous chest pain that lasted > 30 minutes within the preceding 12 hours ST-segment elevation of at least 1 mm in 2 contiguous leads on the 12 leads ECG Infarct related artery (IRA) occlusion (TIMI grade 0) at the angiography Angiographically detected culprit coronary artery lesion deemed suitable for PCI Exclusion Criteria: Contraindications to streptokinase, tirofiban, aspirin, clopidogrel, or heparin Culprit lesion in saphenous vein graft TIMI grade II-III flow in IRA Additional epicardial stenosis in the IRA distal to stented segment (significant or insignificant) Presence of left bundle branch block History of prior MI Mechanical ventilation or inotropic support
Sites / Locations
- Istanbul University, Istanbul School of Medicine, Department of Cardiology
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
1
2
Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed